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Efficacy of Varenicline in Patients With Severe
Alcohol Dependence
A Pilot Double-Blind Randomized and Controlled StudyPhilippe Pfeifer, MD* and Christoph Fehr, MD†‡Abstract:
Purpose/Background: Varenicline has proven its efficacy in the treat-
ment of nicotine dependence, and there is also evidence that it could be
helpful in the treatment of alcohol dependence. In our pilot study, we inves-
tigated the feasibility and acceptability of varenicline for the treatment of a
population of patients with severe alcohol dependence and multiple so-
matic comorbidities after alcohol detoxification.
Methods/Procedures:We conducted a phase II, double-blind, placebo-
controlled randomized trial of daily oral varenicline versus a placebo in
alcohol-dependent men and women after alcohol detoxification (n = 28).
Following our study protocol, somatic conditions and adverse events were
thoroughly monitored and several study end points were investigated
(percentage of abstinent days for both alcohol and nicotine, number of
standardized drinks and cigarettes per day, days of heavy drinking).
Findings/Results: Compared with the placebo, varenicline did not have
more side effects and did not provoke more adverse events. Patients in the
varenicline group did not show a significantly higher percentage of alcohol
abstinent days or fewer heavy drinking days. A trend significance was
found for a reduced number of standard drinks per day (P = 0.06) in the
varenicline group.
Implications/Conclusions: In this pilot trial, varenicline was shown to
be well tolerated by our study population of severely alcohol-dependent
patients with somatic conditions. Varenicline did not sustain alcohol absti-
nence or reduce the number of heavy drinking days, but it did reduce the
daily amount of alcohol consumed.
Key Words: varenicline, alcohol dependence, relapse prevention,
nicotine abstinence
(J Clin Psychopharmacol 2019;00: 00–00)
A lcohol dependence is one of the most disabling conditionsworldwide, leading to severe mental and somatic decline.1
Up until now, less than 20% of patients have received an approved
treatment.2 Hence, the opioid antagonist naltrexone and the gluta-
mate antagonist acamprosate have been approved by the Food and
Drug Administration and in Europe for relapse prevention in
alcohol dependence.3 An interesting substance, among others, for
the treatment of alcohol dependence is the partial α4β2 nicotine
acetylcholine receptor agonist varenicline.4 Varenicline is a Food
and Drug Administration–approved substance for the treatment
of nicotine dependence and has been shown to be highly efficient
and safe in terms of relapse prevention in smoking.5 Therefore,From the *Hospital of Psychiatry Muensingen and University Hospital of Psy-
chiatry Bern, Bern, Switzerland; †Department of Psychiatry, Psychotherapy and
Psychosomatics, Agaplesion Markus Hospital; and ‡Department of Psychiatry,
Psychotherapy and Psychosomatics, University Medical Centre of Frankfurt,
Frankfurt am Main, Germany.
Received December 4, 2018; accepted after revision April 17, 2019.
Reprints: Philippe Pfeifer, MD, Psychiatriezentrum Münsingen, Hunzigenallee 1,
3110 Münsingen, Switzerland (e‐mail: Philippe.Pfeifer@pzmag.ch).
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0271-0749
DOI: 10.1097/JCP.0000000000001056
Journal of Clinical Psychopharmacology • Volume 00, Number 00, Mon
Copyright © 2019 Wolters Kluwer Health, Inc. Unauvarenicline could be of interest in the treatment of patients with
alcohol dependence, as animal models have shown modulation in
the ventral striatal dopamine system in response to varenicline.6
There is growing evidence that nicotine acetylcholine receptors,
which are located in the ventral tegmental area of the brain, modu-
late striatal dopamine pathways and therefore may have a blunting
effect on the rewarding effects of alcohol intake.7 In animal studies,
the acute administration of varenicline reduced alcohol seeking
and voluntary intake in animals exposed chronically to alcohol
compared with the administration of a placebo.8,9
In humans, clinical trials concerning varenicline's effect on
alcohol and nicotine consumption have been conducted on heter-
ogenous groups of clinical populations.10 In a group of nicotine-
dependent patients who were in stable recovery from alcohol
dependence, varenicline promoted smoking abstinence without
enhancing relapses in alcohol drinking.11 In another group,
varenicline reduced cravings for alcohol, the number of heavy
drinking days, the voluntary intake of alcoholic drinks, and the
subjective rewarding effects of alcohol.12 In moderate- and heavy-
drinking patients with alcohol dependence, varenicline had no
effect on alcohol drinking compared with a placebo, but im-
provements in mood and alcohol cravings were noticeable.13 In
a large clinical sample of heavy-drinking outpatients with alcohol
dependence, varenicline significantly reduced alcohol intake and
craving in smokers and nonsmokers alike.14 Larger randomized
trials involving outpatients with alcohol dependence and current
alcohol consumption did not find an effect of varenicline on re-
ducing heavy drinking days.15,16
The aforementioned studies on the effects of varenicline on
nicotine and alcohol consumption were performed predominantly
on alcohol-dependent outpatients without comorbidities. In ad-
dition, concerns about the safety of varenicline in patients with
cardiovascular or neuropsychiatric conditions have been raised.17
Therefore, in our preliminary trial, we focused our investigation
on the safety of varenicline for a group of patients with severe
alcohol and nicotine dependence and organic comorbidities after
detoxification. Furthermore, several outcome measures on drink-
ing and smoking were assessed during the 12-week trial.
MATERIALS AND METHODS
Study Procedure
We conducted a phase II, double-blind, placebo-controlled
randomized trial of daily oral varenicline for patients with alcohol
and nicotine dependence. The investigation was conducted in the
Departments of Psychiatry and Psychotherapy of the Mainz Uni-
versity Medical Centre and the AGAPLESION Markus Hospital
in Frankfurt am Main, Germany. The study was an investigator-
initiated trial at the University Medical Center Mainz. Pfizer
Germany supported the investigator-initiated trial through a study
grant and the provision of the varenicline/placebomedication but was
not involved in conducting the study, data analyses, or publication.th 2019 www.psychopharmacology.com 1
thorized reproduction of this article is prohibited.
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approved by the ethics commission of the State Chamber of Med-
icine in Rheinland-Palatinate, Mainz, and the mandatory German
regulatory authorities (Bundesinstitut für Arzneimittel, Bonn).
The study was carried out in accordance with the Code of Ethics
of the World Medical Association (Declaration of Helsinki) for
experiments involving humans.
Participants
The study participants were recruited in the psychiatric clinics
mentioned previously and by public announcement. The study par-
ticipants were not paid for their participation. To be included, the
participants had to fulfill the criteria for alcohol and nicotine depen-
dence listed in the Diagnostic and Statistical Manual for Mental
Disorders (Fourth Edition). We included man and women between
18 and 65 years of age who had completed alcohol withdrawal
therapy successfully. Each participant had last consumed alcohol
between 7 and 21 days before the baseline study visit. Participants'
motivations for joining the study were assessed by study investi-
gators who had been trained to perform short motivational inter-
ventions. Only participants who clearly stated a motive to abstain
from alcohol were included. The motivation to quit smoking
was not an inclusion criterion. At the time of study inclusion,
participants could be either inpatients or outpatients. All inpa-
tients were discharged from inpatient care between 2 to 7 days
after randomization.
Main Exclusion Criteria for the Study
Any participant with comorbid substance dependence and
psychiatric comorbidities demanding treatment, including schizo-
phrenia, bipolar disorder, major depression, and anxiety; with sui-
cidal ideation as well as a suicidal attempt in their history; and
who was being treated with one of the following substances at
the time of the screening visit: antipsychotics, antidepressants,
mood stabilizers, substances for treatment of alcohol dependence,
benzodiazepines, and opioid analgetics was excluded. Further-
more, subjects with the following diseases were excluded: cardiac
or brain ischemia; malignancy in the past 5 years; cirrhosis of the
liver; acute heart, kidney, or liver diseases; and acute infectious
diseases. Finally, any subject who had epileptic seizures or
deliriant symptoms during their completed withdrawal episode
was excluded.
Study Design
After giving written informed consent, study participants
underwent a baseline visit where inclusion and exclusion criteria
were checked. Three to 7 days later, the participants who met
the inclusion criteria were randomized into the study groups
(varenicline vs placebo). At the screening and the baseline visits,
all participants were instructed to abstain from alcohol. After
randomization, 6 additional visits (in weeks 2, 4, 6, 8, 10, and 12)
and 1 telephone visit (week 1) were conducted. After completion
of the study, one follow-up visit approximately 2weeks after the last
visit was completed. In any case of a severe drinking relapse, inpa-
tient detoxification was advised. In case of an emergency, written
instructions and a telephone number were given to the study partic-
ipants. The following variables were measured during each study
visit: weight, vital signs, breath alcohol concentration, urine drug
screening, breath carbon monoxide (CO) concentration and med-
ical management. Electrocardiogram and routine laboratory (liver
enzymes, basic hematology, bloodminerals, creatinine, carbohydrate-
deficient transferrin) examinations were conducted every 3 weeks.
During each study visit, we measured the amount of plasma γ-
glutamyltransferase (GGT) as a parameter for alcohol consumption2 www.psychopharmacology.com
Copyright © 2019 Wolters Kluwer Health, Inc. Unautand CO as a parameter for smoking. Female participants underwent
a pregnancy test at baseline, at visits 2 and 6, and in any case of
suspected pregnancy. Each study participant was examined by
the responsible study investigator for adverse effects (AEs) dur-
ing each study visit.
Administration of Study Medication
The studymedication was administered orally, with the doses
of varenicline ranging from 0.5mg at the beginning of the study to
1.0 mg after day 7 of the study. The same medication protocol was
observed for both groups: in the first 3 days of the study, both
study groups received one tablet in the morning (0.5 mg
varenicline or the placebo). From days 4 to 7, all participants
received 2 tablets per day, one in the morning and one at noon
(2  0.5 mg varenicline or the placebo). From day 8 until the
end of the study, each participant received 2 tablets per day, one
in themorning and one at noon (2 1.0 varenicline or the placebo).
Therapy adherence was monitored during the regular study visits.
At each study visit, the participants received the exact amount of
medication needed until the next study visit, including instructions
for intake. The participants were asked to return a blister that was
checked for correct intake, and they had to report tablet intake at
each visit.
Assessment of Clinical Parameters
Drinking behavior was assessed via the time line followback
method.18 During each study visit, the participants reported on
their daily drinking amounts as well as number of cigarettes per
day since the last study visit (for the last 90 days before the screen-
ing visit). Subjective responses (eg, 1 L of beer) were converted
into the number of standard drinks (eg, 4 standard drinks). One
standard drink indicated 12 g of alcohol. Severity and length of
alcohol dependencewere assessed using the European Addiction
Severity Index.19 Severity of nicotine dependence was assessed
by using the Fagerstrom Test for nicotine dependence.20 Depressed
moodwas assessed by using theHamiltonDepression Scale and the
Beck Depression Inventory at each study visit.21,22 Subjects who
scored higher than 12 on the Hamilton Depression Scale or 9 on
the Beck Depression Inventory were considered to be depressed
and excluded from the study. Alcohol craving was measured using
the Obsessive Compulsive Drinking Scale.23
Study End Points
The primary end point was defined as the percentage of days
without alcohol consumption during treatment. In addition, a
deduced percentage of abstinent days was calculated by defining
undocumented days (eg, after early study termination) as days
with alcohol consumption. The main secondary end points were
as follows: (i) number of standardized drinks during treatment,
(ii) percentage of heavy drinking days, (iii) number of cigarettes
per day, and (iv) percentage of nicotine abstinence days. Safety
end points comprised adverse events (coded according toMedDRA
17.0), concomitant medication, and psychiatric assessment. Ad-
verse effects comprised neuropsychiatric as well as gastrointesti-
nal, dermatologic, and allergic side effects.
Statistical Analyses
Details of the statistical analysis were documented in a Statis-
tical Analysis Plan that was finalized before closing the database.
The Statistical Analysis Plan was based on the protocol, including
all amendments. Analyses of primary and secondary end points
were based on the intention-to-treat population comprising all
randomized patients. The primary analysis compared the rate
of alcohol abstinence days between treatment groups using an© 2019 Wolters Kluwer Health, Inc. All rights reserved.
horized reproduction of this article is prohibited.
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α = 5%). All secondary end points were analyzed on an explor-
atory basis using appropriate tests that depended on the scale of
the parameter. Fisher exact test was used to analyze the number
of patients with sustained abstinence in terms of alcohol con-
sumption. The percentage of heavy drinking days and the percent-
age of nicotine abstinent days were analyzed using the t test. The
Wilcoxon rank sum test andWilcoxon sign rank test were used to
analyze the number of standardized drinks and number of cig-
arettes per day, respectively. Cohen d was used to calculate the
effect size for the reduced standard drinks and cigarettes. Cohen d
is an effect size that is used to indicate the standardized difference
between 2 means. An effect size smaller than 0.5 is termed small,
an effect size between 0.5 and 0.8 is considered to be medium and
an effect size greater than 0.5 is thought of as large.24 The time to
first serious drinking was estimated using Kaplan-Meier and the
corresponding log-rank test. For the analysis of changes in bio-
markers, we performed an analysis of covariance test with GGT
and CO as the dependent variables, and the covariables were
varenicline and placebo group and changes to baseline.
RESULTS
Sample Population and Clinical Characteristics
From July 2010 to July 2013, we recruited 28 subjects.
Fifteen subjects were randomized to the varenicline group, and
13 subjects were randomized to the placebo group. The demo-
graphic variables and the histories of alcohol and nicotine depen-
dence are shown in Table 1.
Considering all the participants, 20.0% (n = 3) from the
varenicline group completed the trial following the regular proto-
col, whereas none from the placebo group managed to do so. The
reasons for dropping out of the study included a lack of motivation
and time and alternative therapy options, among others. Two sub-
jects from the varenicline group dropped out because of adverse
effects (increased body temperature, fatigue) despite a low therapeutic
dose (0.5 mg/d). The number of AEs was comparable in bothTABLE 1. Demographic Data and History of Alcohol and Nicotine A
Varenicline (n = 15)
Age, mean (SD), y 45.73 (9.27)
Sex
Female 2 (13.33%)
Male 13 (86.67%)
No. years with problematic alcohol consumption*
n 15
Mean (SD) 12.27 (7.84)
No. years with alcohol dependence*
n 15
Mean (SD) 9.00 (5.93)
No. withdrawal therapies
n 15
Mean (SD) 8.33 (10.71)
Median 4
Started to smoke (age in years)†
n 15
Mean (SD) 18.07 (6.81)
*European Addiction Severity Index.
†Fagerstrom Test for Nicotine Dependence.
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
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significant differences in the AEs in the neuropsychiatry, al-
lergy, and dermatology categories. Subjects in the varenicline
group had a slightly higher risk for nausea (8.1%) compared
with the placebo group (1.8%). The overall therapy adherence
was 88.5% (±23.0%; P = 0.76).
Study End Points
The primary and secondary end points of the intention-
to-treat analyses are presented in Table 2. With regard to the pri-
mary end point, which was defined as the rate of abstinent days
within the 12-week period of treatment, no statistically significant
difference between the 2 groups was found (P = 0.58). The mean
(SD) percentage of abstinent days in the varenicline group was
83.3% (24.1%) compared with 87.9% (15.4) in the placebo group.
The participants consumed an overall average (SD) of 21.5
(11.9) standardized drinks per day in the 90 days before random-
ization (varenicline: 21.0 [12.1], P = 0.12; placebo: 22.1 [12.2],
P = 0.68). During the treatment, we observed a reduction in stan-
dardized drinks per day in the varenicline group, with a total mean
(SD) number of 11.4 (12.2) drinks per day (P = 0.06; d = 0.79). In
the placebo group, we observed a reduction 1.3 drinks, on aver-
age, with a total mean (SD) number of 21.0 (11.9) drinks per
day (P = 0.44, d = 0.09). Although the reduction was somewhat
greater in the varenicline group, the difference in reduction be-
tween the groups did not reach statistical significance (P = 0.17,
Table 2). The percentages of heavy drinking days during the study
for the 2 groups were not significantly different (varenicline:
10.6%; placebo: 10.8%, P = 0.98). During the course of the
study, the plasma GGT decreased in both groups. Carbohydrate-
deficient transferrin decreased in both study groups from 2.86%
to 1.67% (mean) in the varenicline group and from 3.38% to 1.73%
(mean) in the placebo group.
With regard to nicotine dependence, at the beginning of the
study, most of the participants were moderately to severely depen-
dent (Fagerstrom test mean (SD) score, 5.6 [2.9]). There was no
statistical difference between both groups. The number of cigarettes
per day showed a mean (SD) of 18.1 (9.5) in the varenicline groupbuse—ITT Population (n = 28)
Placebo (n = 13) Total (n = 28)
44.15 (6.84) 45.00 (8.12)
2 (15.38%) 4 (14.29%)
11 (84.62%) 24 (85.71%)
13 28
16.08 (8.91) 14.04 (8.42)
13 28
11.46 (8.98) 10.14 (7.46)
13 28
3.54 (3.28) 6.11 (8.38)
3 3
13 28
18.54 (3.07) 18.29 (5.32)
www.psychopharmacology.com 3
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TABLE 2. Primary and Secondary Therapy End Points—ITT Population (n = 28)
Varenicline (n = 15) Placebo (n = 13) P*
Percentage of abstinent alcohol days after
randomization, percent (SD)
83.3 (24.1) 87.9 (15.4) 0.58†
Standard drinks per day
Before treatment, mean (SD) 21.0 (12.1) 22.1 (12.2) 0.68‡
After randomization, mean (SD) 11.4 (12.2) 21.0 (11.9) 0.12‡
Reduction in the standard drinks per day
No. −11.3 (11.1) −1.3 (9.1) 0.17‡
Wilcoxon rank sum test P = 0.06 P = 0.44
Percentage of nicotine abstinence days after
randomization, percent (SD)
5.4 (17.8) 0.7 (2.3) 0.40§
No. cigarettes per day
Before treatment, mean (SD) 26.2 (13.4) 25.9 (10.2) 0.73*
After randomization, mean (SD) 18.1 (9.5) 20.5 (10.4) 0.49*
*P < 0.05 indicates a significant difference between groups.
†Analysis of variance.
‡Wilcoxon rank sum test.
§t Test.
Pfeifer and Fehr Journal of Clinical Psychopharmacology • Volume 00, Number 00, Month 2019compared with 20.5 (10.4) in the placebo group, but there was no
significant difference in cigarette consumption (P = 0.49). Com-
pared with the mean number of cigarettes per day at baseline
(varenicline: mean [SD], 26.2 [13.4]; placebo: mean [SD], 25.9
[10.2]), a statistically significant reduction was observed in both
groups (varenicline, P = 0.001; placebo,P = 0.001). However, there
was no statistically significant difference between the 2 groups
(P = 0.23). The percentage of nicotine abstinence days in the
varenicline group (5.4% [17.8%]) was slightly higher than that in
the placebo group (0.7% [2.3]), but the difference was not sta-
tistically significant (P = 0.4). Carbon monoxide values de-
creased significantly in both groups compared with baseline
(P < 0.0001), but no difference was observed between the
varenicline and the placebo groups (P = 0.60). Alcohol craving
(Obsessive Compulsive Drinking Scale score) was comparable
in both groups at baseline (varenicline: mean [SD], 9.4 [6.5];
placebo: mean [SD], 12.9 [9.6]). During the treatment, a mean
reduction in craving was found in both groups at the end of the
study (mean scores, 4.2 for varenicline and 5.5 for placebo).DISCUSSION
In this preliminary trial, we tested the acceptability and
efficacy of varenicline in a cohort of detoxified patients with
severe alcohol dependence. With regard to the primary end point,
that is, the percentage of abstinent days for alcohol, varenicline
did not show a significant effect compared with placebo. In the
varenicline group, there was a trend toward a reduction in the
number of daily standard drinks consumed.
There has been a controversial discussion of varenicline in
the literature with regard to neuropsychiatric syndromes and car-
diovascular diseases.5,25 In our study sample of severely ill pa-
tients, the AEs and dropout rates due to the pharmacological
adverse effects of varenicline were not higher than the dropout
rates for the placebo group. Therefore, our results confirm the re-
sults of a recently published trial that showed no increase in neu-
ropsychiatric AEs in psychiatric and nonpsychiatric patients.26
Several studies have investigated the effect of varenicline on
drinking parameters in alcohol use disorders previously.14–17,26,27
Our finding that varenicline had no effect on alcohol abstinence4 www.psychopharmacology.com
Copyright © 2019 Wolters Kluwer Health, Inc. Unautcorresponds to the results of 3 other studies.14–16 Otherwise, our
study confirms the finding of 2 previous studies that varenicline
reduces the daily alcohol intake but has no positive effect on heavy
drinking days.12,15 It is noteworthy that our study participants con-
sumed about twice the mean dose of alcohol per day compared
with participants in the study by Litten et al.15 Although the find-
ings in our study were not statistically significant, there was a me-
dium effect size for the reduction of daily alcohol intake in the
varenicline group. There were no effects of varenicline on alcohol
cravings in our study. This finding corresponds to previous studies
that found no or only small effects of varenicline in reducing alco-
hol craving.12,27 However, in contrast to our participants, the latter
study samples consisted mainly of heavy-drinking smokers
seeking treatment of smoking. Furthermore, patients in our
investigation underwent detoxification before treatment and
may have experienced stronger cravings than those patients not
undergoing withdrawal.
We found only a modest reduction in smoking for the sub-
jects taking varenicline, despite the fact that the latter is well estab-
lished as a pharmacological treatment of nicotine dependence.27
In contrast, other studies found a positive effect of varenicline
on nicotine consumption in heavy-drinking subjects and a positive
correlation between the reduction in cigarette smoking and the
consumption of alcohol.17,26 However, that some participants in
our study had no explicit aim to quit smoking may explain the
reduced efficacy of varenicline in reducing smoking.
We recognize the limitations of our study: because of a re-
strictive approach with multiple exclusion criteria, we were not
able to recruit more study participants. Our study results are lim-
ited to a small sample size and should be perceived of as prelimi-
nary. However, a real drug-placebo difference cannot be excluded
andmay be obscured by the small number of subjects and the high
variability present. Another limitation is the low retention rate of
participants in the study. This low retention may be due to
the severity of the dependence, leading to a higher frequency
of drinking relapses of stronger severity.
In summary, varenicline was safe and well tolerated in a
naturalistic clinical population of patients who were severely
affected by alcohol dependence as well as by other comorbidi-
ties. Although varenicline was effective in reducing the number© 2019 Wolters Kluwer Health, Inc. All rights reserved.
horized reproduction of this article is prohibited.
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sures of alcohol and nicotine consumption.
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